New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nifedipine 90mg (15mg in core, 75mg in core coating) - film coated tablet - 90 mg - active: nifedipine 90mg (15mg in core, 75mg in core coating) excipient: crospovidone hydrated silica hyprolose hypromellose iron oxide red lactose monohydrate macrogol 4000 magnesium stearate maize starch microcrystalline cellulose

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - nifedipine extended-release tablets, usp are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions , drug interactions . ) nifedipine must not be used in cases of cardiogenic shock. nifedipine is contraindicated in patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 90 mg - nifedipine extended-release tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions: drug interactions. ) nifedipine must not be used in cases of cardiogenic shock. nifedipine extended-release tablets are contraindicated in patients with a known hypersensitivity to any component of the tablet. the safety and effectiveness of nifedipine in pediatric patients have not been established. although small pharmacokinetic studies have identified an increased half-life and increased c max and auc (see clinical pharmacology: pharmacokinetics and metabolism ), clinical studies of nifedipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not id

United States - English - NLM (National Library of Medicine)

alvogen inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - nifedipine extended-release tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions, drug interactions .)  nifedipine must not be used in cases of cardiogenic shock. nifedipine is contraindicated in patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - nifedipine extended-release tablets, usp are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions, drug interactions. ) nifedipine must not be used in cases of cardiogenic shock. nifedipine is contraindicated in patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 90 mg - nifedipine extended-release tablets, usp are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions , drug interactions ) nifedipine must not be used in cases of cardiogenic shock. nifedipine is contraindicated in patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - nifedipine extended-release tablets is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. known hypersensitivity to nifedipine.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 60 mg - nifedipine extended-release tablets is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. known hypersensitivity to nifedipine.

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - nifedipine extended-release tablets, usp are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions , drug interactions . ) nifedipine must not be used in cases of cardiogenic shock. nifedipine is contraindicated in patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 60 mg - nifedipine extended-release tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions: drug interactions. ) nifedipine must not be used in cases of cardiogenic shock. nifedipine extended-release tablets are contraindicated in patients with a known hypersensitivity to any component of the tablet. the safety and effectiveness of nifedipine in pediatric patients have not been established. although small pharmacokinetic studies have identified an increased half-life and increased cmax and auc (see clinical pharmacology: pharmacokinetics and metabolism ), clinical studies of nifedipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not ide